AbbVie Inc. buy Simon1
Start price
03.05.20
/
50%
€75.80
Target price
04.11.21
€85.00
Performance (%)
14.45%
End price
12.02.21
€86.75
Summary
This prediction ended on 12.02.21 with a price of €86.75. The BUY prediction by Simon1 finished with a performance of 14.45%. Dividends of €3.12 are taken into consideration when calculating the performance. Simon1 has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| AbbVie Inc. | -0.909% | -0.909% | 6.410% | 71.797% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% | 12.563% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% | 41.078% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% | 0.655% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% | 39.960% |